Navigation Links
Boston Scientific Comments on New England Journal of Medicine Article
Date:1/23/2008

results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

617-459-2703 (mobile)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Boston IVF is First in Northeast to Offer Pioneering Test of Womens Biological Clock
2. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
3. Boston Scientific Announces Court Decision
4. Boston Scientific to Participate in JP Morgan Health Care Conference
5. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
6. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
7. Boston University Medical Center researcher honored
8. ESi Announces Strategic New Hire in Boston
9. Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
10. Boston Scientific to Participate in BMO Capital Markets Healthcare Conference
11. Boston University School of Medicine Professor receives award from American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... 28, 2015 , ... Inc. magazine today ranked PREVENT Life Safety ... nation’s fastest-growing private companies. The list was unveiled online at Inc.com and is the ... last three years, PREVENT ranks higher on the list than any other company in ...
(Date:8/28/2015)... ... 28, 2015 , ... The Wilson and Juanita Mann Health ... improving a patient’s quality of life through early diagnosis and treatment. The focus ... diabetes, HIV/AIDS, STDs, and others. A Women’s, Infants & Children (WIC) clinic also ...
(Date:8/27/2015)... ... August 28, 2015 , ... This new webinar educates providers about how can ... for the next visit, their authorizations are in check, and they are current with ... Barnes, COO for Genesis Chiropractic Software, growing a practice depends on patient experience and ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... cost to treat a patient with hemophilia is $175,000. Hemophilia is an inherited, ... and improving treatment. The RMHBDA exists to help raise funds for patients suffering ...
(Date:8/27/2015)... ... ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. Mark Carney announced today that ... on Saturday, August 29, 2015 at the Marriott DTC, 4900 S. Syracuse Street, Denver, ... will present a two part seminar entitled, “How to Thrive as You Age & ...
Breaking Medicine News(10 mins):Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2Health News:Health Clinic Opening and Public Art Unveiling 2Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2
... discovered a potent and highly-debilitating toxin in the endangered ... now prompting investigations of other marine mammals in the ... marine algae common on coral reefs, and accumulates in ... human disease caused by ciguatoxin, affects thousands of people ...
... parental abuse as a child increases a person,s chances of ... research article in the current issue of the ... (Volume 66B, Number 3). An analysis of data ... early parental emotional abuse was associated with a higher number ...
... reports, lawsuits, congressional inquiries, claims and counterclaims, the question ... people lacks a definitive answer, according to a package ... edition of Chemical & Engineering News (C&EN), ACS,s weekly ... K. Ritter explains that BPA has been used in ...
... of nuclear stress tests, More women than men are ... studies ordered by primary care physicians ... Island and The Miriam hospitals suggests a possible gender ... tests, an imaging technique that measures blood flow to ...
... new generation of highly localized wireless networks that are ... from monitoring the functioning of implants, to tracking the ... But if this emerging technological area is to mature ... definition of its scope and potential, and a clearer ...
... ADDRESS SHORTAGE IN THE ICU , Intensive care ... worsen in the future. A recent study, conducted by ... Medical Center in New York, NY, studying 590 daytime ... non-physician providers can help address these staff shortages. ...
Cached Medicine News:Health News:Seniors abused during childhood face increased risk of sleep troubles 2Health News:Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals 2Health News:Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals 3Health News:The future of wireless body area networks is the focus of a June 19-20 workshop at WPI 2Health News:The future of wireless body area networks is the focus of a June 19-20 workshop at WPI 3Health News:Chest journal news briefs -- June 2011 issue 2
(Date:8/27/2015)... 2015 The nation,s newest Actos trial gets underway ... Vegas courtroom.  Attorneys representing two southern ... effects, including death, after using the diabetes drug Actos. ... a company knew, that their drug Actos caused an increased ... "In order to hold Takeda responsible it is appropriate to ...
(Date:8/27/2015)... HARRISBURG, Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular ... and second in the United States ... a new type of stent for blockages in the main ... flexibility within the artery and potentially less risk for stent ... MIMICS-2 is a prospective, single-arm, multicenter clinical trial of the ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, Inc. ... development of Next Generation Photonic Devices and ... in high speed fiber-optic data communications and optical ... has been appointed to the Company,s Board ... the field of optoelectronics is widely recognized with ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3
... New Sites, BERKELEY HEIGHTS, N.J., Oct. 17 ... the French Health Products,Safety Agency ("AFSSAPS") has granted ... Genasense(R) (oblimersen sodium) Injection, its lead,anticancer compound, in ... of approximately 13 new investigative sites over the,next ...
... Venture Between Bristol-Myers Squibb, Company and ... HIV Treatment -, PRINCETON, N.J. and FOSTER ... (NYSE: BMY ) and Gilead Sciences, Inc.,(Nasdaq: ... has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil ...
Cached Medicine Technology:Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency 2Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
Near PT test card/4 1/2 to 12 PT in spanish & french /5 1/2" X 8....
Card has Jaeger rating and snellen equivalent....
Near point card 4 1/2 to 24 PT 5 1/2" x 8"....
... is specially designed to be a corrected Rosenbaum ... card (as noted by Horton and Jones in ... notations are not used because of the lack ... Wormington NP Card, the examiner can measure a ...
Medicine Products: